Filing Flows › Health Care › Anteris Technologies Global (AVR)
Anteris Technologies Global (AVR) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Anteris Technologies Global (AVR) Q2 2026 earnings results →
Q2 2026 Revenue up 63% year over year to $1.0M
Anteris Technologies Global made $1.0M in Q2 2026 (+63% Y/Y). Operating margin n/m, net loss $28.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.0M in Q2 2026, up 63% year over year and up 104% from the previous quarter.
Operating costs exceeded revenue by $31.0M, an operating margin of -3072.1%. Total costs grew 49% against revenue growth of 63%. The fastest-growing cost line was SG&A (+68%). The quarter ended with a net loss of $28.8M, wider than the previous quarter's $22.9M loss.
Operating cash flow was −$20.8M. Non-cash charges added back $469K of depreciation and amortization and $2.1M of share-based compensation. Working capital and other items added $5.4M. Capital expenditures of $648K exceeded it, leaving free cash flow of −$21.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $1.0M | +63% | n/m | −$28.8M | −$20.8M |
| Q1 2026 | 10-Q | May 12, 2026 | $494K | -11% | n/m | −$22.9M | −$28.7M |
| Q4 2025 | 10-K | Feb 26, 2026 | $310K | -42% | n/m | −$29.0M | −$18.5M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $429K | -44% | n/m | −$22.2M | −$18.3M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $618K | -2% | n/m | −$21.1M | −$19.5M |
| Q1 2025 | 10-Q | May 13, 2025 | $556K | -27% | n/m | −$21.9M | −$21.5M |
| Q4 2024 | 10-K | Mar 12, 2025 | $536K | — | n/m | −$19.2M | −$18.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Anteris Technologies Global
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR ® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR ® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.
In its own words, from its 8-K, filed Aug 12, 2026.
Anteris Technologies Global against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +63% against the peers' median +10%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AVR Anteris Technologies Global | Q2 2026 | $1.0M | +63% | n/m |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: Anteris Technologies Global 10-Q on SEC EDGAR · CIK 2011514 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
13F: who owns AVR and who is buying
More on AVR
- How Anteris Technologies Global makes money: revenue by segment
- Anteris Technologies Global next earnings date and what analysts expect
- Anteris Technologies Global stock forecast, price target and fair value
- Who owns Anteris Technologies Global stock: holders, funds and Congress trades
- Anteris Technologies Global recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results